Summary:
- Kelun Biotech, a biopharmaceutical company, presented the results of multiple clinical studies on their TROP2-ADC (Antibody-Drug Conjugate) Sacituzumab Tirumotecan at the 2025 CCHIO Congress.
- TROP2-ADC is a targeted cancer therapy that delivers a potent chemotherapy drug directly to cancer cells, potentially improving the effectiveness of treatment while reducing side effects.
- The clinical studies demonstrated promising results in treating various types of cancer, highlighting the potential of this innovative approach to cancer treatment.